Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study

INTRODUCTION: Spebrutinib (CC-292) is an orally administered, covalent, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK), part of the B-cell and Fc receptor signaling pathways. This study evaluated spebrutinib pharmacology and mechanism of action over a 4-week treatment period in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Schafer, Peter H., Kivitz, Alan J., Ma, Jianglin, Korish, Shimon, Sutherland, Donna, Li, Li, Azaryan, Ada, Kosek, Jolanta, Adams, Mary, Capone, Lori, Hur, Eun Mi, Hough, Douglas R., Ringheim, Garth E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021855/
https://www.ncbi.nlm.nih.gov/pubmed/31721017
http://dx.doi.org/10.1007/s40744-019-00182-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021855/
https://www.ncbi.nlm.nih.gov/pubmed/31721017
http://dx.doi.org/10.1007/s40744-019-00182-7

Ejemplares similares